SEC Comment Letter 0000000000-24-004590 to Enliven Therapeutics, Inc. (ELVN) (CIK 0001672619) (ELVN)
Enliven Therapeutics, Inc. (ELVN) (CIK 0001672619)
Date: April 24, 2024 · CIK: 0001672619 · Accession: 0000000000-24-004590
AI Filing Summary & Sentiment
File numbers found in text: 333-278801
Letter
United States securities and exchange commission logo April 24, 2024 Samuel Kintz Chief Executive Officer Enliven Therapeutics, Inc. 6200 Lookout Road Boulder, CO 80301 Re:Enliven Therapeutics, Inc. Registration Statement on Form S-3 Filed April 18, 2024 File No. 333-278801 Dear Samuel Kintz: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Rachel Nagashima, Esq.
Show Raw Text
United States securities and exchange commission logo
April 24, 2024
Samuel Kintz
Chief Executive Officer
Enliven Therapeutics, Inc.
6200 Lookout Road
Boulder, CO 80301
Re:Enliven Therapeutics, Inc.
Registration Statement on Form S-3
Filed April 18, 2024
File No. 333-278801
Dear Samuel Kintz:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Doris Stacey Gama at 202-551-3188 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Rachel Nagashima, Esq.